PP405 Overview, Dosing & Safety | Peptide Database

PP405 (JXL-069)

MPC Inhibitor | Hair Follicle Stem Cell Activation

Community Research

Join others researching PP405 — share findings, ask questions, and learn from real experiences

PP405 is an investigational topical drug developed by Pelage Pharmaceuticals for the treatment of androgenetic alopecia. Based on research conducted at UCLA, PP405 works through a fundamentally different mechanism than existing hair loss treatments: rather than blocking androgens like finasteride or promoting blood flow like minoxidil, it targets the metabolic dormancy of hair follicle stem cells directly. By inhibiting the mitochondrial pyruvate carrier (MPC1/MPC2), PP405 causes pyruvate accumulation in hair follicle stem cells, stimulating lactate dehydrogenase activity and triggering a metabolic shift that reactivates dormant follicles. Phase 2a clinical trial results showed increased hair count and thickness with a 0.05% gel formulation applied once daily. As of 2025, the drug has completed Phase 2a trials, with Phase 3 trials planned for 2026.

PP405 is a dual inhibitor of the mitochondrial pyruvate carrier complex, targeting both the MPC1 and MPC2 subunits. Under normal conditions, the MPC transports pyruvate from the cytoplasm into the mitochondrial matrix, where it enters the tricarboxylic acid (TCA) cycle for oxidative metabolism. In hair follicle stem cells (HFSCs), this standard metabolic pathway is associated with quiescence and dormancy. By blocking MPC1/MPC2, PP405 prevents pyruvate from entering the mitochondria, causing it to accumulate in the cytoplasm. This pyruvate buildup stimulates lactate dehydrogenase (LDH) activity, which converts pyruvate to lactate, shifting the cell's metabolic profile toward aerobic glycolysis. This metabolic reprogramming mimics the signaling environment that naturally triggers HFSCs to exit quiescence and re-enter the cell cycle. The activated stem cells then initiate a new anagen (growth) phase in dormant hair follicles. Critically, this mechanism is entirely independent of the androgen/DHT pathway targeted by finasteride and dutasteride, and distinct from the vasodilatory effects of minoxidil, meaning PP405 could be effective regardless of a patient's androgen status.

Molecular Data

Research Indications

Currently in Phase 2 clinical trials for the treatment of androgenetic alopecia. Phase 2a results showed measurable increases in hair count and thickness with the 0.05% topical gel formulation.

PP405 directly targets metabolic dormancy in hair follicle stem cells by inhibiting MPC1/MPC2 and promoting anagen re-entry. This mechanism may address follicle miniaturization at an earlier stage than androgen-blocking approaches.

Dosing Protocols

PP405 is formulated as a 0.05% topical gel for once-daily application to the scalp. This is the only formulation currently under clinical investigation. The topical route delivers the active compound directly to the hair follicle environment while minimizing systemic absorption. Application involves a thin layer of gel spread across affected areas of the scalp.

Androgenetic alopecia treatment (Phase 2 trial protocol)

0.05% gel

Once daily

Topical application to scalp

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Scalp irritation at the application site

Application site reactions (redness, dryness, itching)

Stop Signs - Discontinue if:

Severe or persistent scalp irritation that does not resolve

Signs of allergic reaction (significant swelling, rash spreading beyond the application site)

Any unexpected systemic symptoms following application

Contraindications

Known hypersensitivity to PP405 or any component of the gel formulation

Full contraindication profile has not been established (investigational drug)

Pregnant or breastfeeding women should avoid use until safety data is available

Quality Checklist

Good Signs

Obtained through an authorized clinical trial site or Pelage Pharmaceuticals directly

Properly labeled with lot number, expiration date, and clinical trial identifiers

Stored per protocol instructions provided by the trial site

Prescribed or dispensed by a licensed investigator as part of an approved clinical trial

Warning Signs

Products marketed as 'PP405' or 'JXL-069' from research chemical vendors are NOT verified by Pelage Pharmaceuticals

Any product claiming to be PP405 that is not sourced from an active clinical trial

Grey market formulations with unverified concentrations or purity

Bad Signs

Research chemical vendor products sold as PP405 or JXL-069 without regulatory oversight

Products without certificate of analysis, batch numbers, or manufacturer information

Any PP405 product purchased outside of a regulated clinical trial or pharmacy setting

Formulations with undisclosed ingredients or unverifiable provenance

Frequently Asked Questions

Can I stack PP405 with finasteride and minoxidil for better results?

Yes, PP405's stem cell activation mechanism is completely complementary to finasteride's DHT reduction and minoxidil's vasodilation. This triple combination targets hair loss from three angles—androgenic suppression, blood flow, and metabolic stem cell reactivation—making it theoretically superior to any single agent.

How is PP405 different from finasteride if both treat hair loss?

Finasteride blocks DHT hormone production systemically, while PP405 directly reactivates dormant hair follicle stem cells locally via metabolic reprogramming. PP405 doesn't affect hormones, making it potentially effective regardless of androgen status and stackable with existing treatments without hormonal complications.

When will I see results from PP405?

Phase 2a trials showed measurable hair count and thickness increases by week 12-24 with daily 0.05% topical application. Results depend on how many follicles are dormant vs. permanently lost—earlier-stage hair loss responds better than advanced miniaturization.

Is PP405 safer than oral hair loss drugs?

Yes—as a topical with minimal systemic absorption, PP405 avoids the sexual dysfunction and hormonal concerns associated with oral 5-alpha reductase inhibitors, though long-term human safety data remains limited since trials are still ongoing.

References

Phase 2a clinical trial evaluating the safety, pharmacokinetics, and efficacy of PP405 topical gel in adults with androgenetic alopecia. The study assessed the 0.05% gel formulation applied once daily, with endpoints including hair count, hair thickness, and safety measures.

UCLA research demonstrating that manipulation of the lactate/pyruvate metabolic axis in hair follicle stem cells can drive these cells out of quiescence. Inhibiting mitochondrial pyruvate carriers causes cytoplasmic pyruvate accumulation, activates lactate dehydrogenase, and promotes a glycolytic shift that triggers hair follicle stem cell activation and anagen entry. This foundational research underpins the mechanism of action of PP405.

Related Peptides

Completely different mechanisms of action. Finasteride blocks DHT production via 5-alpha reductase inhibition, while PP405 targets hair follicle stem cell metabolism via MPC inhibition. Combination could be synergistic by addressing both hormonal miniaturization and stem cell dormancy simultaneously.

Different mechanisms of action. Minoxidil promotes vasodilation and extends the anagen phase through potassium channel opening, while PP405 reactivates dormant stem cells via metabolic reprogramming. No known contraindications for combined use.

Different mechanisms of action. Dutasteride inhibits both Type I and Type II 5-alpha reductase to block DHT, while PP405 acts on mitochondrial pyruvate carriers in hair follicle stem cells. No overlapping pathways suggest safe co-administration.

Different mechanisms of action. RU-58841 is a topical androgen receptor antagonist, while PP405 targets stem cell metabolism independently of the androgen pathway. Both are topically applied, but to different molecular targets.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.